Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Abstract

Abstract The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.

Keywords

Affiliated Institutions

• Brigham and Women's Hospital US
• Harvard University US
• Universität Ulm DE
• Assistance Publique – Hôpitaux de Paris FR
• Australian Centre for HIV and Hepatitis Virology Research AU
• Hospital Universitari i Politècnic La Fe ES
• Hôpital Saint-Louis FR
• King's College London GB
• Monash University AU
• Universitat de València ES
• Hospital de Sant Pau ES
• Leipzig University DE
• Erasmus MC NL
• Josep Carreras Leukaemia Research Institute ES
• The Alfred Hospital AU
• University of Rome Tor Vergata IT
• University of Chicago US
• Fred Hutch Cancer Center US
• University of Münster DE
• National Hospital Organization JP
• The Ohio State University US
• Nagoya Medical Center JP
• Vrije Universiteit Amsterdam NL
• Memorial Sloan Kettering Cancer Center US
• National Taiwan University Hospital TW

Related Publications